A 19-year-old using topical minoxidil and dutasteride reports significant hair growth and shedding. Minoxidil caused new facial hair growth, and the user hopes for thicker hair regrowth.
And minoxidil.
This user posted progress pictures after using a combination of minoxidil and finasteride over a 2.5 month period, which received various comments from other users with differing opinions.
The user has been using Morr-F Aqua 5% (minoxidil) once daily for over three months to address male pattern baldness and is seeking feedback on their progress. They are unsure if the current dosage is sufficient and whether the aqueous base is effective compared to other versions.
A user shared their 2-month progress using a topical solution with 6% Minoxidil and 0.3% Finasteride, applied nightly with a dropper. They reported no side effects and plan to update every 2 months.
User shared 3.5 months of hair regrowth progress using oral minoxidil 2.5 mg and microneedling, noting a younger appearance. Replies included congratulations and comments on the impressive results.
The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.
Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.
The user reported positive progress in hair regrowth after two months using finasteride, topical minoxidil, microneedling, and ketoconazole, later switching to dutasteride. Some users doubted the authenticity of the results, while others were impressed and encouraged by the progress.
PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
The user has been using topical finasteride and minoxidil for a month to address hair thinning. They are experiencing shedding but have noticed small hairs on their temples.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
The user "Curious_Conflict_959" shared a progress picture of their hair transplant after 5 months. They used a low dosage of RU on native hairs and had PRP treatments. All hair loss has stopped.
Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.
The user aims to achieve a hypertrichosis look and has used topical Minoxidil for 20 years, now trying oral Minoxidil in a low dose. They seek alternatives to Minoxidil to avoid side effects.
User shared progress after 5 months of using finasteride, minoxidil foam, and weekly derma rolling. Positive feedback highlights increased hair count and thickness.
The user shared a two-year update on hair loss treatment using oral minoxidil, finasteride, and microneedling, noting significant progress after starting oral treatments and microneedling. They began treatment in early 2023 after noticing hair loss in late 2021.
A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.
The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.
The user is seeking before-and-after photos of hair growth results from using oral or topical Minoxidil, as they couldn't use Finasteride but are using RU58841. They are curious about the effectiveness of Minoxidil alone.
Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.
The user experienced positive hair growth results using microneedling with rosemary and mint oil, without Minoxidil, Finasteride, or RU58841. They switched from a dermaroller to a microneedling pen and targeted different scalp areas weekly.
The conversation discusses hair loss treatments, including topical and oral minoxidil, finasteride, RU58841, and microneedling. Users suggest adding oral dutasteride or finasteride for more effective results.
The user resumed finasteride and added 5mg oral minoxidil and biotin, noticing quick progress in hair regrowth. Other users discuss dosages and express surprise at the results.
The user shared progress on hair regrowth using a topical minoxidil/finasteride spray, dermarolling weekly, and a product similar to pp405. They reported some regrowth with no side effects from the new product.
The user shared a 4-month update on their hair regrowth journey using finasteride, minoxidil, and microneedling, reporting significant progress and styling ability. They emphasized persistence, shared their regimen details, and addressed side effects like weaker erections and blurry vision, which improved with lifestyle changes.
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
A 31-year-old male shared his 4.5-month progress using finasteride, topical minoxidil, and dutasteride mesotherapy for hair loss, showing significant improvement in crown density and overall hair texture. He reported no side effects and plans to continue the treatment to assess further results.
User shared 16-month progress using finasteride 1 mg/day and minoxidil 5% solution once/day, noting significant regrowth, especially in temporal peaks. Users discussed shedding, side effects, and positive feedback from others.
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.